Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines

Clinical and Vaccine Immunology

Volumn 14, Issue 9, 2007, Pages 1062-1069

  Sandbu, Synne ^a   Feiring, Berit ^a   Oster, Philipp ^b   Helland, Oddveig S ^a   Bakke, Hilde S W ^a   Næss, Lisbeth M ^a   Aase, Audun ^a   Aaberge, Ingeborg S ^a   Kristoffersen, Anne Cathrine ^a   Rydland, Kjersti M ^a   Tilman, Sandrine ^c   Nøkleby, Hanne ^a   Rosenqvist, Einar ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Novartis Vaccines BCDM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MENINGOCOCCOSIS; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; PHAGOCYTOSIS; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; BACTERIAL OUTER MEMBRANE PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; VACCINES, COMBINED;

EID: 34948901495     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00094-07     Document Type: Article

References (31)

1. Aase, A., L. M. Naess, R. H. Sandin, T. K. Herstad, F. Oftung, J. Holst, I. L. Haugen, E. A. Høiby, and T. E. Michaelsen. 2003. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21:2042-2051.
2. Bjune, G., E. A. Høiby, J. K. Grønnesby, O. Arnesen, J. H. Fredriksen, A. Halstensen, E. Holten, A. K. Lindbak, H. Nøkleby, and E. Rosenqvist. 1991. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:1093-1096.
3. Borrow, R., I. S. Aaberge, G. F. Santos, T. L. Eudey, P. Oster, A. Glennie, J. Findlow, E. A. Høiby, E. Rosenqvist, P. Balmer, and D. Martin. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976.
4. Borrow, R., P. Balmer, and E. Miller. 2005. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 23:2222-2227.
5. Boutriau, D., J. Poolman, R. Borrow, J. Findlow, J. Diez Domingo, J. Puig-Barbera, J. M. Baldo, V. Planelles, A. Jubert, J. Colomer, A. Gil, K. Levie, A. D. Kervyn, V. Weynants, F. Dominguez, R. Barbera, and F. Sotolongo. 2006. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vaccine Immunol. 4:65-73.
6. de Kleijn, E., L. van Eindhoven, C. Vermont, B. Kuipers, H. van Dijken, H. Rumke, R. de Groot, L. van Alphen, and G. van den Dobbelsteen. 2001. Serum bactericidal activity and isotype distribution of antibodies in toddlers and schoolchildren after vaccination with RIVM hexavalent PorA vesicle vaccine. Vaccine 20:352-358.
7. Dyet, K., A. Devoy, R. McDowell, and D. Martin. 2005. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery. Vaccine 23:2228-2230.
8. Feiring, B., J. Fuglesang, P. Oster, L. M. Næss, O. S. Helland, S. Tilman, E. Rosenqvist, M. A. Bergsaker, H. Nøkleby, and I. S. Aaberge. 2006. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin. Vaccine Immunol. 13:790-796.
9. Frasch, C. E., L. van Alpen, J. Holst, J. T. Poolman, and E. Rosenqvist. 2001. Outer membrane protein vesicle vaccines for meningococcal disease. In A. J. Pollard and M. C. J. Maiden (ed.), Methods in molecular medicine, vol. 66. Meningococcal vaccines. Humana Press, Totowa, NJ.
10. Holst, J., B. Feiring, J. E. Fuglesang, E. A. Høiby, H. Nøkleby, I. S. Aaberge, and E. Rosenqvist. 2003. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734-737.
11. Holst, J., I. S. Aaberge, P. Oster, D. Lennon, D. Martin, J. O'Hallahan, K. Nord, H. Nøkleby, L. M. Næss, K. Møyner, P. Kristiansen, A. G. Skryten, K. Bryn, A. Aase, R. Rappuoli, and E. Rosenqvist. 24 July 2003. A 'tailor made' vaccine trialled as part of public health response to group B meningococcal epidemic in New Zealand. Eurosurv. Wkly. http://www.eurosurveillance.org/ew/2003/030724.asp#5.
12. Luijkx, T., H. van Dijken, C. van Els, and G. van den Dobbelsteen. 2006. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine. Vaccine 24:1569-1577.
13. Michaelsen, T. E., and A. Aase. 2001. Antibody-induced opsonophagocytosis of serogroup B meningococci measured by flow cytometry, p. 331-337. In A. J. Pollard and M. C. J. Maiden (ed.), Methods in molecular medicine, vol. 66. Meningococcal vaccines. Humana Press, Totowa, NJ.
14. Ministry of Health. 8 Aug 2006. Meningococcal B Immunisation Programme effectiveness shown. http://www.moh.govt.nz/moh.nsf/pages/MH5042.
15. Moe, G. R., P. Zuno-Mitchell, S. N. Hammond, and D. M. Granoff. 2002. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect. Immun. 70:6021-6031.
16. Næss, L. M., T. Torill, A.-C. Kristoffersen, I. S. Aaberge, E. A. Høiby, and E. Rosenqvist. 2002. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines, p. 284. In D. A. Caugant and E. Wedege (ed.), Abstr. 13th Int. Pathogenic Neisseria Conf., Oslo 2002. Nordberg Aksidenstrykkeri AS, Oslo, Norway.
17. Noah, N., and B. Henderson. 2002. Surveillance of bacterial meningitis in Europe 1999/2000. Abridged version. Communicable Disease Surveillance Center, Public Health Laboratory Service, London, United Kingdom. http://www.hpa.org.uk/hpa/inter/m_surveillance9900.pdf. Accessed 23 August 2006.
18. Nøkleby, H., and B. Feiring. 1991. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann. 14:95-102.
19. Nøkleby, H., P. Aavitsland, J. O'Hallahan, B. Feiring, S. Tilman, and P. Oster. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25:3080-3084.
20. Oster, P., D. Lennon, J. O'Hallahan, K. Mulholland, S. Reid, and D. Martin. 2005. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23:2191-2196.
21. Oster, P., J. O'Hallahan, I. Aaberge, S. Tilman, E. Ypma, and D. Martin. 2007. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 25:3075-3079.
22. Rosenqvist, E., E. A. Høiby, E. Wedege, K. Bryn, J. Kolberg, A. Klem, E. Rønnild, G. Bjune, and H. Nøkleby. 1995. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect. Immun. 63:4642-4652.
23. Ross, S. C., P. Rosenthal, H. M. Berberich, and P. Densen. 1987. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J. Infect. Dis. 155:1266-1275.
24. Sexton, K., D. Lennon, P. Oster, S. Crengle, D. Martin, K. Mulholland, et al. 2004. The New Zealand meningococcal vaccine strategy: a tailor-made vaccine to combat a devastating epidemic. N. Z. Med. J. 117:U1015.
25. Sierra, G. V., H. C. Campa, N. M. Varcacel, I. L. Garcia, P. L. Izquierdo, P. F. Sotolongo, G. V. Casanueva, C. O. Rico, C. R. Rodriguez, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann. 14:195-207.
26. Tappero, J. W., R. Lagos, A. M. Ballesteros, B. Plikaytis, D. Williams, J. Dykes, L. L. Gheesling, G. M. Carlone, E. A. Høiby, J. Holst, H. Nøkleby, E. Rosenqvist, G. Sierra, C. Campa, F. Sotolongo, J. Vega, J. Garcia, P. Herrera, J. T. Poolman, and B. A. Perkins. 1999. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 281:1520-1527.
27. Thornton, V., D. Lennon, K. Rasanathan, J. O'Hallahan, P. Oster, J. Stewart, S. Tilman, I. Aaberge, B. Feiring, and H. Nøkleby. 2006. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24:1395-1400.
28. Toropainen, M., L. Saarinen, G. Vidarsson, and H. Kayhty. 2006. Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats. Infect. Immun. 74:2803-2808.
29. Tzanakaki, G., and P. Mastrantonio. 2007. Aetiology of bacterial meningitis and resistance to antibiotics of causative pathogens in Europe and in the Mediterranean region. Int. J. Antimicrob. Agents 29:621-629.
30. van den Dobbelsteen, G. P., H. H. van Dijken, S. Pillai, and L. van Alphen. 2007. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 25:2491-2496.
31. Wyle, F. A., M. S. Artenstein, B. L. Brandt, E. C. Tramont, D. L. Kasper, P. L. Altieri, S. L. Berman, and J. P. Lowenthal. 1972. Immunologic response of man to group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126:514-522.